The initial expansion will create 205 new jobs, including 85 in the Clayton facility, which currently produces a number of products, including the Levemir FlexPen (insulin detemir [rDNA origin] injection) and other products for the entire diabetes portfolio, Novo Nordisk said.

The expansion will include the addition of two final assembly lines, two packing lines and building refurbishment.

Novo Nordisk president Jerzy Gruhn said that as patients in the US continue to move from administering insulin with a conventional vial and syringe to using a pen device, Novo Nordisk will be prepared to meet growing market demand,” Gruhn said.

The Clayton expansion project is approved to receive incentive support from a Job Development Investment Grant and a One North Carolina Fund grant and the company’s final decision is contingent upon final approval of local government incentives by Johnston County and Buncombe County.